Head-to-head Study of Upadacitnib and Dupilumab in Atopic Dermatitis (Level Up)

Author(s):

An atopic dermatitis expert describes the results of the Level Up study, a phase 3b/4 trial comparing upadacitinib and dupilumab, which were recently presented at RAD 2024, focusing on the primary and secondary outcomes of the study.

EP: 1.Systemic Treatments in Atopic Dermatitis: Use and Treatment Inertia

EP: 2.Atopic dermatitis Clinical Trial Endpoints

EP: 3.Treatment and Patient Reported Outcomes in Atopic Dermatitis

Now Viewing

EP: 4.Head-to-head Study of Upadacitnib and Dupilumab in Atopic Dermatitis (Level Up)

EP: 5.Ongoing Studies in Atopic Dermatitis and Recommendations for Clinicians

Head-to-head studies of systemic treatments and studies evaluating sequencing of systemic treatments are rare. Results of one such study, Level Up, were recently presented at RAD 2024. Can you describe the study briefly and discuss primary and secondary outcomes in phase 3b/4 study that compared upadacitnib and dupilumab (Level Up, RAD 2024)?
What are implications of these results in everyday practice?